📰 前沿資訊/免疫前沿

免疫檢查點抑制劑的作用機制與臨床應用現況

Immune Checkpoint Inhibitors: Mechanisms of Action and Current Clinical Applications

📅 2026-06-25📌 來源:Cancer Link 癌研連線 編輯部
免疫學研究實驗室內研究人員在電腦螢幕前查看細胞影像數據

在我二十多年的腫瘤科臨床工作中,最常被病人問到的問題之一就是:「醫生,什麼是免疫治療?它跟化療有什麼不同?」

這個問題問得非常好。讓我用一個比喻來解釋。

想像你的身體是一座花園。正常的花園裡有園丁——也就是你的免疫系統——每天巡邏,看到雜草(異常細胞)就會拔掉。但癌細胞很狡猾,它們會穿上「隱形斗篷」,讓園丁認不出它們。免疫治療的工作,就是幫園丁脫掉癌細胞的斗篷,或給園丁一副「透視眼鏡」,讓免疫系統重新看見並攻擊癌細胞。

化療則是完全不同的思路——化療像是用強力的除草劑,不管好細胞壞細胞一起清除,所以才會有掉頭髮、口腔潰爛、白血球下降等副作用。免疫治療相對來說更「聰明」,它主要針對免疫系統發指令,對正常細胞的影響較小。

目前臨床上常用的免疫治療藥物主要是「免疫檢查點抑制劑」。這個名詞聽起來很嚇人,但你可以把它理解為「免疫系統的煞車解除器」。正常情況下,免疫系統有「煞車」來防止它攻擊自己的器官。癌細胞會偷偷踩下這個煞車來保護自己。免疫檢查點抑制劑就是把這個煞車鬆開,讓免疫系統恢復攻擊力。

在我治療過的病人中,有一位六十多歲的肺癌患者張先生讓我印象特別深刻。他剛來的時候已經是多處轉移的晚期,走路都會喘。經過免疫治療後,他不僅腫瘤明顯縮小,現在每天早上還能去公園打太極拳。當然,免疫治療不是對每個人都有效,大約只有兩到三成的晚期患者能明顯獲益——但它一旦有效,效果往往持久。

哪些人比較適合免疫治療?這需要醫師通過檢測來判斷,主要看腫瘤細胞上的「PD-L1表達量」和「微衛星不穩定性」等指標。你可以把這些檢測想像成「看癌細胞的習慣」,了解它的弱點在哪裡。

免疫治療雖然比化療的副作用輕,但也不是完全沒有不適。因為免疫系統被「喚醒」後,有時會誤傷正常器官,可能出現皮疹、腹瀉、甲狀腺功能異常,甚至肺炎。關鍵是要「早發現、早處理」——有任何不適都要馬上告訴醫療團隊,不要自己忍著。

最後我想說:如果你或你的家人正在考慮免疫治療,請不要把它當作「最後的救命稻草」而過度焦慮。把它看作治療旅程中的一個新夥伴——它不一定能創造奇蹟,但在適合的人身上,它可以帶來很長時間的穩定和良好的生活品質。

癌症治療的路很長,但你不是一個人在走。

English Version

In my 20+ years as an oncologist, one of the most common questions I hear is: "Doctor, what exactly is immunotherapy?"

Let me explain with a simple metaphor. Imagine your body as a garden. Your immune system is like a gardener who patrols daily, pulling out weeds (abnormal cells). But cancer cells are sneaky — they wear an "invisibility cloak" that hides them from the gardener. Immunotherapy works by removing that cloak, or giving the gardener special glasses, so the immune system can see and attack cancer cells again.

Unlike chemotherapy — which is like applying a strong herbicide that affects both weeds and healthy plants — immunotherapy is more targeted. It primarily sends instructions to the immune system, with less impact on normal cells.

The most common immunotherapy drugs today are "immune checkpoint inhibitors." Think of them as releasing the brakes that cancer cells have applied to your immune system. Once the brakes are off, your immune cells can do their job again.

Not everyone responds to immunotherapy — about 20-30% of advanced cancer patients see significant benefit. But when it works, the response can be remarkably durable. Doctors use tests like PD-L1 expression and MSI status to identify who is most likely to benefit.

Side effects are generally milder than chemotherapy, but they do exist. The key is early detection and early management — never hesitate to report any discomfort to your medical team.

Immunotherapy isn't a miracle cure, but for the right person, it can bring extended stability and good quality of life. The cancer journey is long, but you are not walking it alone.

📚 參考文獻:

1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355. 2. Postow MA, et al. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:158-168. 3. NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities. Version 1.2026.

← 返回資訊列表